UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 |
Form 6-K |
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 |
For the month of: November, 2003 |
Commission File Number: 000-50393 |
NEUROCHEM INC. |
7220 Frederick-Banting, Suite 100 Saint-Laurent, Québec H4S 2A1 |
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F |_| Form 40-F |X| |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): |
Yes |_| No |X| |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): |
Yes |_| No |X| |
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g-3 under the Securities Exchange Act of 1934. |
Yes |_| No |X| |
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): |
SIGNATURES: |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. |
NEUROCHEM INC. | ||
November 7, 2003 | ||
By: | /s/ David Skinner David Skinner Director of Legal Affairs and General Counsel |
Neurochem Inc. 7220 Frederick-Banting, Suite 100 Saint-Laurent, Qc H4S 2A1 Canada | |
NEUROCHEM TO PRESENT AT CIBC WORLD MARKETS FOURTEENTH ANNUAL HEALTHCARE CONFERENCE |
SAINT-LAURENT, CANADA, November 6, 2003 – Neurochem, Inc. ( NASDAQ: NRMX, TSX: NRM) announced today that it will present at the CIBC World Markets 14th Annual Healthcare Conference taking place from November 10th to 12th, 2003 at the Plaza Hotel in New York City. Dr. Francesco Bellini, Neurochem’s Chairman and CEO, will deliver the presentation on Monday, November 10, 2003 at 8:30 am Eastern time. A copy of the Company’s presentation will be available on the Neurochem’s Web site athttp://www.neurochem.com/Investor.htm#Presentation. |
About Neurochem |
Neurochem is focused on the development and commercialization of innovative therapeutics for neurological disorders. The Company’s staged pipeline of proprietary, disease-modifying, oral products addresses critical unmet medical needs. FibrillexTM, designated an orphan drug, is in a Phase II/III clinical trial for AA amyloidosis. AlzhemedTM has completed a Phase II clinical trial for the treatment of Alzheimer’s disease. CerebrilTM is in a Phase II trial for the prevention of hemorrhagic stroke caused by cerebral amyloid angiopathy. Neurochem is also developing a product for the potential treatment of epileptic seizures induced by traumatic brain injury. For additional information on Neurochem, please visit our website at: (www.neurochem.com) This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the common shares in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state. |
-30- |
Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond Neurochem’s control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which Neurochem does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation as well as other risks included in public filings of Neurochem. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance on the forward-looking statements included in this news release. These statements speak only as of the date made and Neurochem is under no obligation and disavows any intention to update or revise such statements as a result of any event, circumstances or otherwise. |
-2- |
For further information, please contact: |
Lise Hebert, Ph.D. Vice President, Corporate Communications lhebert@neurochem.com Tel: (514) 337-4646 Cell: (514) 924-7394 |
Nathalie Bourque | Francesca DeVellis | ||
National Public Relations | Ogilvy PR | ||
nbourque@national.ca | francesca.devellis@ogilvypr.com | ||
Tel: (514) 843-2309 | Tel: (617) 308-8543 (cell phone) | ||
Cell: (514) 953-2155 | Fax: (617) 577-8985 |